4CPS-090 Emtricitabine/elvitegravir/cobicistat/tenofovir: effects on lipid metabolism and renal function
| Autor: | M Miguelez, M Suárez, E Gomez, J Merino, M Navarro, G Calzado, T Betancor, E Ramos, P. Diaz, A Ferrer, Miguel Angel Cajigal Vera |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Creatinine Triglyceride Elvitegravir Cholesterol business.industry Cobicistat Renal function Retrospective cohort study Emtricitabine Gastroenterology chemistry.chemical_compound chemistry Internal medicine medicine business Section 4: Clinical pharmacy services medicine.drug |
| Zdroj: | Eur J Hosp Pharm |
| Popis: | Background Emtricitabine/elvitegravir/cobicistat/tenofovir (FTC/EVG/COBI/TAF) changes levels of cholesterol and triglyceride. Purpose To assess the effect on lipid metabolism and renal function in patients with human immunodeficiency virus (HIV) treated with the antiretoviral FTC/EVG/COBI/TAF. Material and methods Retrospective study from November 2016 to April 2017. VIH patients who started treatment with FTC/EVG/COBI/TAF and had blood tests before and after treatment initiation (3 and 6 months after initiation) were included. Data were obtained from the Farmatools outpatients program and from the electronic medical history software Drago AE. We compared pre- and post-treatment values of total cholesterol, plasma triglycerides, serum creatinine and creatinine clearance (crCl). We considered that a variation in analytical data had ocurred if there were differences greater than 10 mg/dL in total cholesterol and triglycerides values, and 0.1 mg/dL in creatinine (Cr) values. Results A total of 62 patients were included in the study, 69.1% (47) males and 30.9% (21) females, mean patient age was 30 years (18–79). Overall, 10 of them were naive patients, 30 patients were previously treated with FTC/EVG/COBI/tenofovir disoproxil fumarate (TFD), 21 patients were previously treated with another antiretroviral therapy containing TDF and one patient switched from monotherapy with viral protease inhibitors. Also, 67.6% of patients (46) presented a mean increase of 86.09±67.7 mg/dL in their triglyceride levels (median increase of 63 mg/dL). As for total cholesterol, 82.3% of patients (56) showed a mean elevation of 39.07±17.5 mg/dL (median of 41 mg/dL). Regarding the creatinine and crCl values, none of the patients had a creatinine clearance below 60 mg/dl. Overall, 76.4% of the patients (52) showed a mean decrease of 0.22±0.12 mg/dL (median of 0.17 mg/dL). None of the patients showed an increase in their creatinine values. Conclusion With the new antiretroviral FTC/EVG/COBI/TAF, an increase in total cholesterol and triglyceride levels was observed in most patients. An improvement in serum creatinine values was also seen. Taking these results into account, it would be necessary to study in greater depth and with a greater number of patients to determine the clinical consequences of these first data obtained in real life. References and/or Acknowledgements Hospital Candelaria. No conflict of interest |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|